Vytrus Biotech S.A. - Asset Resilience Ratio

Latest as of December 2025: 0.00%

Vytrus Biotech S.A. (VYT) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check VYT strategic asset allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets

€600.00
≈ $701.46 USD Cash + Short-term Investments

Total Assets

€14.66 Million
≈ $17.14 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2020–2025)

This chart shows how Vytrus Biotech S.A.'s Asset Resilience Ratio has changed over time. See Vytrus Biotech S.A. (VYT) net asset quality to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Vytrus Biotech S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see VYT company net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €600.00 0.0%
Total Liquid Assets €600.00 0.00%

Asset Resilience Insights

  • Limited Liquidity: Vytrus Biotech S.A. maintains only 0.00% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Vytrus Biotech S.A. Industry Peers by Asset Resilience Ratio

Compare Vytrus Biotech S.A.'s asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Revolution Medicines Inc
NASDAQ:RVMD
Biotechnology 65.10%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Hugel Inc
KQ:145020
Biotechnology 29.57%
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Biotechnology 39.07%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
Biotechnology 2.30%
Absci Corp
NASDAQ:ABSI
Biotechnology 59.86%
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
Biotechnology 5.52%
Lifecome Biochemistry Co Ltd
SHE:002868
Biotechnology 4.69%

Annual Asset Resilience Ratio for Vytrus Biotech S.A. (2020–2025)

The table below shows the annual Asset Resilience Ratio data for Vytrus Biotech S.A..

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 0.00% €600.00
≈ $701.46
€14.66 Million
≈ $17.14 Million
0.00pp
2024-12-31 0.01% €600.00
≈ $701.46
€11.13 Million
≈ $13.01 Million
0.00pp
2023-12-31 0.01% €600.00
≈ $701.46
€9.31 Million
≈ $10.89 Million
0.00pp
2021-12-31 0.01% €520.00
≈ $607.93
€7.18 Million
≈ $8.40 Million
0.00pp
2020-12-31 0.01% €740.00
≈ $865.14
€6.21 Million
≈ $7.26 Million
--
pp = percentage points

About Vytrus Biotech S.A.

MC:VYT Spain Biotechnology
Market Cap
$159.93 Million
€136.80 Million EUR
Market Cap Rank
#18110 Global
#117 in Spain
Share Price
€18.20
Change (1 day)
+1.11%
52-Week Range
€3.98 - €19.80
All Time High
€19.80
About

Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Lon… Read more